LB Pharmaceuticals (LBRX) Registration filing summary

Company overview and business model

• Late-stage biopharmaceutical company focused on novel therapies for neuropsychiatric disorders, including schizophrenia, bipolar depression, and major depressive disorder.

• Lead candidate LB-102 is a methylated derivative of amisulpride, designed for improved therapeutic profile and IP protection.

• LB-102 is in late-stage clinical development for schizophrenia and bipolar depression, with plans for Phase 2 trial in adjunctive MDD.

• U.S. branded antipsychotic market estimated at $12 billion in 2024, with significant unmet need for improved risk-benefit profiles.

Financial performance and metrics

• Completed IPO in September 2025, raising capital through the sale of 21,850,000 shares at $15.00 per share.

• February 2026 private placement raised additional funds at $21.17 per share and via pre-funded warrants.

• No dividends declared or paid; all earnings retained for business growth and development.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling stockholders, except nominal amounts from warrant exercises.

• Proceeds from IPO and private placements intended to support operations, R&D, and pipeline advancement.